Hypoxia targeted gene therapy to increase the efficacy of tirapazamine as an adjuvant to radiotherapy: reversing tumor radioresistance and effecting cure.
D000256:Adenoviridae / Q000235:genetics; D000818:Animals; D015687:Cell Hypoxia; D005260:Female; D015316:Genetic Therapy; D006801:Humans; D007770:L-Lactate Dehydrogenase / Q000235:genetics*; D051379:Mice; D009251:NADPH-Ferrihemoprotein Reductase / Q000235:genetics*; D009374:Neoplasms, Experimental / Q000628:therapy*; D011836:Radiation Tolerance; D018714:Radiotherapy, Adjuvant; D020218:Response Elements; D000077704:Tirapazamine; D014227:Triazines / Q000627:therapeutic use*
D014227:Triazines; D000077704:Tirapazamine; D007770:L-Lactate Dehydrogenase; D009251:NADPH-Ferrihemoprotein Reductase